Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET).
- DOI
- 10.1016/j.ekir.2017.02.019
- Published
- 2017 Jul
- Container
- Kidney international reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ekir.2017.02.019,
title = {Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET).},
author = {Komers R and Gipson DS and Nelson P and Adler S and Srivastava T and Derebail VK and Meyers KE and Pergola P and MacNally ME and Hunt JL and Shih A and Trachtman H},
year = {2017},
journal = {Kidney international reports},
doi = {10.1016/j.ekir.2017.02.019},
url = {https://doi.org/10.1016/j.ekir.2017.02.019}
}RIS
TY - JOUR TI - Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET). AU - Komers R AU - Gipson DS AU - Nelson P AU - Adler S AU - Srivastava T AU - Derebail VK AU - Meyers KE AU - Pergola P AU - MacNally ME AU - Hunt JL AU - Shih A AU - Trachtman H PY - 2017 JO - Kidney international reports DO - 10.1016/j.ekir.2017.02.019 UR - https://doi.org/10.1016/j.ekir.2017.02.019 ER -
APA
R, K., DS, G., P, N., S, A., T, S., VK, D., KE, M., P, P., ME, M., JL, H., A, S., & H, T. (2017). Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET).. Kidney international reports. https://doi.org/10.1016/j.ekir.2017.02.019
Source records
- pubmed · retrieved 2026-09-25T16:42:06.210Z
- europe-pmc · retrieved 2026-09-25T16:42:06.231Z
- doaj · retrieved 2026-09-25T16:42:06.295Z